
The zzso administration of zzso therapy significantly reduces the morbidity and mortality associated with zzso zzso episodes in zzso zzso zzso zzso zzso therapy can be safely administered to a subset of zzso zzso patients at low risk for clinical zzso 

zzso cancer patients presenting with zzso zzso after zzso chemotherapy and who met institutional criteria for early hospital discharge following a minimum of zzso zzso zzso intravenous zzso were eligible for the zzso The feasibility and efficacy of an zzso continuation therapy of oral zzso zzso zzso zzso divided zzso and zzso zzso zzso zzso divided zzso was zzso 

Thirty zzso zzso episodes in 26 patients were treated with zzso oral zzso zzso zzso zzso therapy was feasible in 28 zzso and zzso in 26 zzso of treatment zzso zzso was discontinued due to abdominal pain and zzso zzso zzso zzso zzso fever zzso zzso zzso or gastrointestinal bleeding zzso zzso zzso No patient developed new zzso or zzso zzso zzso pain or gastrointestinal symptoms occurred in zzso of treatment zzso zzso of zzso lower absolute zzso count zzso zzso zzso at start of oral zzso therapy and active zzso disease were associated with failure of oral zzso zzso 

It is feasible to administer oral zzso as continuation zzso therapy for a selected zzso of zzso zzso episodes defined after initial hospitalization and zzso zzso zzso zzso zzso trials will be required to analyze adequately the efficacy of an oral zzso zzso zzso regimen for treatment of zzso zzso in pediatric zzso zzso 

